Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Comprehensive Overview
Published in the New England Journal of Medicine in 2017, this study, known as the FOURIER trial, asked whether evolocumab, an antibody drug that blocks a protein called PCSK9 and lowers LDL cholesterol by roughly 60%, could actually prevent heart attacks and strokes rather than simply improving a lab value, a question earlier trials of this drug class had not been large or long enough to answer. Researchers conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with established atherosclerotic cardiovascular disease and an LDL cholesterol level of 70 milligrams per deciliter or higher despite already taking statin therapy. Patients were randomly assigned to receive evolocumab, injected under the skin either every 2 weeks or monthly according to preference, or matching placebo, and were followed for a median of 2.2 years. The primary outcome was a composite of cardiovascular death, heart attack, stroke, hospitalization for unstable angina, or coronary revascularization, with a key secondary outcome limited to cardiovascular death, heart attack, or stroke. The topline result was that evolocumab lowered LDL cholesterol to a median of just 30 milligrams per deciliter and significantly reduced the risk of both outcomes.
Outcomes and Implications
The most important finding was that evolocumab significantly reduced the primary composite outcome, occurring in 9.8% of patients on evolocumab versus 11.3% on placebo, a 15% relative risk reduction, and reduced the key secondary outcome of cardiovascular death, heart attack, or stroke by 20%, from 7.4% to 5.9%. Individually, evolocumab lowered the risk of heart attack by 27%, stroke by 21%, and coronary revascularization by 22%, though it had no measurable effect on cardiovascular death or death from any cause specifically during the trial's follow-up period. Notably, the magnitude of benefit grew over time rather than shrinking, with the risk reduction for the primary outcome rising from 12% in the first year to 19% beyond it, suggesting the cardiovascular benefits of very low LDL cholesterol accumulate the longer a patient stays on treatment. The benefit was consistent regardless of a patient's starting LDL level, including among those already in the lowest quartile, and regardless of background statin intensity or ezetimibe use. Evolocumab was well tolerated overall, with no significant difference from placebo in serious adverse events, new-onset diabetes, allergic reactions, or neurocognitive problems, addressing earlier theoretical concerns about very low LDL levels, though injection-site reactions were modestly more common. The authors conclude that adding evolocumab to statin therapy lowered LDL cholesterol to a median of 30 milligrams per deciliter and meaningfully reduced cardiovascular events, providing evidence that patients with established atherosclerotic disease benefit from pushing LDL cholesterol well below currently recommended targets.